High incidence of BCL-6 gene rearrangement in diffuse large B-cell lymphoma of primary gastric origin

被引:22
作者
Liang, R [1 ]
Chan, WP [1 ]
Kwong, YL [1 ]
Xu, WS [1 ]
Srivastava, G [1 ]
Ho, FCS [1 ]
机构
[1] UNIV HONG KONG,QUEEN MARY HOSP,DEPT PATHOL,HONG KONG,HONG KONG
关键词
D O I
10.1016/S0165-4608(96)00388-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The incidence of BCL-6 gene rearrangement was studied in 39 Hong Kong Chinese patients with diffuse large B-cell lymphoma. The primary site of involvement was nodal in 18 cases and gastric in 21 cases. Clonal BCL-6 gene rearrangement was found in 27% of the patients with primary nodal and 48% with primary gastric lymphoma (p = 0.05). The clinical characteristics and treatment outcome of the 22 patients with primary gastric lymphoma were analyzed according to the BCL-6 status. Significantly more patients in the germline BCL-6 gene group had advanced stage (ll, III and IV) of disease. Complete remission rate following primary therapy appeared to be higher for the positive rearrangement group (70% versus 36%), but it was not statistically significant. Those with a rearranged BCL-6 gene also appeared to have better survival at 5 years (58% versus 36%) but the difference was also not statistically significant. On the other hand, patients being classified as low risk according to the International Prognostic Index had significantly better survival at 5 years (89% versus 9%, p = 0.0001). We concluded that BCL-6 gene rearrangement was more commonly found in diffuse large B-cell lymphoma of primary gastric origin than its nodal counterpart and it may be playing a more important role in the pathogenesis of gastric large B-cell lymphoma. There was a trend that the BCL-6 gene rearrangement was associated with a more favorable outcome in patients with gastric large B-cell lymphoma but the difference was not statistically significant. (C) Elsevier Science Inc., 1997.
引用
收藏
页码:114 / 118
页数:5
相关论文
共 26 条
[1]   IDENTIFICATION OF THE GENE ASSOCIATED WITH THE RECURRING CHROMOSOMAL TRANSLOCATIONS T(3,14)(Q27,Q32) AND T(3,22)(Q27,Q11) IN B-CELL LYMPHOMAS [J].
BARON, BW ;
NUCIFORA, G ;
MCCABE, N ;
ESPINOSA, R ;
LEBEAU, MM ;
MCKEITHAN, TW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (11) :5262-5266
[2]  
BASTARD C, 1994, BLOOD, V83, P2423
[3]  
CABANILLAS F, 1982, BLOOD, V60, P693
[4]  
CARBONE PP, 1971, CANCER RES, V31, P1860
[5]  
CAVALLI F, 1996, ANN ONCOL S3, V7, P3
[6]   COMBINATION CHEMOTHERAPY IN TREATMENT OF ADVANCED HODGKINS DISEASE [J].
DEVITA, VT ;
SERPICK, AA ;
CARBONE, PP .
ANNALS OF INTERNAL MEDICINE, 1970, 73 (06) :881-+
[7]   CLINICOPATHOLOGICAL FEATURES OF MALIGNANT-LYMPHOMAS IN 294 HONG-KONG CHINESE PATIENTS, RETROSPECTIVE STUDY COVERING AN 8-YEAR PERIOD [J].
HO, FCS ;
TODD, D ;
LOKE, SL ;
NG, RP ;
KHOO, RKK .
INTERNATIONAL JOURNAL OF CANCER, 1984, 34 (02) :143-148
[8]   IMMUNOHISTOLOGICAL SUBTYPES OF NON-HODGKINS-LYMPHOMA IN HONG-KONG CHINESE [J].
HO, FCS ;
LOKE, SL ;
HUI, PK ;
TODD, D .
PATHOLOGY, 1986, 18 (04) :426-430
[9]  
HOOGSTRATEN B, 1984, CANCER CLIN TRIALS, P139
[10]  
*INT NONH LYMPH PR, 1993, NEW ENGL J MED, V329, P987